Abbott Laboratories (ABT) Upgraded to Buy at Rothschild & Co

Market Context

Abbott Laboratories operates in the Healthcare sector. The stock currently trades at $100.29 with a market capitalization of $202.5B. The stock has declined 22.3% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Rothschild & Co's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Abbott Laboratories

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 02, 2026	Rothschild & Co	Buy	N/A
Sep 08, 2026	TD Cowen	Buy	N/A
Aug 25, 2026	TD Cowen	Buy	N/A
Aug 13, 2026	Wolfe Research	Outperform	N/A
Jul 28, 2026	UBS	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View ABT Stock Page